TTD | Drug: D09WYL

Drug General Information
Drug ID	D09WYL
Former ID	DIB010428
Drug Name	GSK-557296
Synonyms	Epelsiban; Epelsiban besylate; Premature ejaculation therapeutic (oral), GlaxoSmithKline
Drug Type	Small molecular drug
Indication	Premature ejaculation [ICD9: 302.75; ICD10:F52.4]		Phase 2	[522869]
Company	GlaxoSmithKline plc
Structure		Download 2D MOL 3D MOL
Formula	C30H38N4O4
Canonical SMILES	C1CN(CCO1)C(=O)[C@H](N1[C@@H](C(=O)N[C@@H](C1=O)C1Cc2c(<br />C1)cccc2)[C@@H](C)CC)c1c(nc(cc1)C)C
PubChem Compound ID	11634973
Target and Pathway
Target(s)	Oxytocin receptor	Target Info	Antagonist	[532286]
KEGG Pathway	Calcium signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Oxytocin signaling pathway
NetPath Pathway	TGF_beta_Receptor Signaling Pathway
PANTHER Pathway	Oxytocin receptor mediated signaling pathway
Reactome	Vasopressin-like receptors
Reactome	G alpha (q) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Myometrial Relaxation and Contraction Pathways
	Oxytocin signaling
	Gastrin-CREB signalling pathway via PKC and MAPK
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 522869	ClinicalTrials.gov (NCT01021553) A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation. U.S. National Institutes of Health.
Ref 532286	Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information